E. Berger

Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

A. Stamatoullas, P. Fenaux, L. Adès, 2012, British journal of haematology.

Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.

B. Coiffier, E. Wattel, P. Fenaux, 1994, Leukemia.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Leukemia.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

A. Stamatoullas, P. Fenaux, L. Adès, 2005 .

Fotemustine Combined with Procarbazine in Recurrent Malignant Gliomas: A Phase I Study with Evaluation of Lymphocyte O6-alkylguanine–DNA Alkyltransferase Activity

A. Silvani, G. Margison, A. Watson, 2001, Journal of Neuro-Oncology.

Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis.

L. Hoyer, M. Hultin, B. Coller, 1981, Blood.

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts).

J. Hainsworth, T. Ciuleanu, L. Hart, 2006, Journal of Clinical Oncology.

Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.

B. Coiffier, C. Sebban, C. Dumontet, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.